Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01825707 · ClinicalTrials.gov registry record · Phase 1
AME Study of [14C]-YH4808 in Healthy Male Subjects
A Phase 1 study, sponsored by Yuhan Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01825707 is a Phase 1 study that has completed, run by Yuhan Corporation. The registered enrollment target is 8 participants.
The verdict
NCT01825707, a Phase 1 study, has completed, sponsored by Yuhan Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the absorption, metabolism, and excretion (AME) kinetics of YH4808 and to determine and characterize metabolites present in plasma, urine, and feces in man following a single dose of \[14C\] YH4808 200 mg (\~100 µCi ±20 µCi) administered as a single oral dose.
Interventions
- DRUG [14C]-YH4808 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01825707
The ClinicalTrials.gov registry entry for NCT01825707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yuhan Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-YH4808 200 mg is the first listed.
NCT01825707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01825707 about?
NCT01825707 is a clinical study titled "AME Study of [14C]-YH4808 in Healthy Male Subjects". The purpose of this study is to determine the absorption, metabolism, and excretion (AME) kinetics of YH4808 and to determine and characterize metabolites present in plasma, urine, and feces in man following a single dose of \[14C\] YH4808 200 mg (\~100 µCi ±20 µCi) administered as a single oral dos...
What is the current status of trial NCT01825707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-01. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01825707?
The interventions under investigation include: [14C]-YH4808 200 mg (DRUG).
Who is sponsoring clinical trial NCT01825707?
This trial is sponsored by Yuhan Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.